Ryzodeg (insulin degludec;insulin aspart)
- Region
- 🇪🇺 EU
- Active substance
- insulin degludec;insulin aspart
- Company
- Novo Nordisk A/S
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus
- CHMP opinion
- Thu 18 Oct 2012
- EU approval
- Mon 21 Jan 2013
- Application
- EMEA/H/C/002499
- ATC
- A10AD06
- Official record
- www.ema.europa.eu
Indication
Treatment of diabetes mellitus in adults, adolescents and children from the age of 2 years.
Regulatory milestones
No milestones recorded in the last year.
Follow Ryzodeg
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.